Across TCGA pan-cancer cohorts, UBE3C Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated UBE3C data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in kidney chromophobe (KICH), where higher UBE3C Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated UBE3C expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.
KICH, UCEC, and SARC are the cancer types where UBE3C Mutation most reproducibly stratifies survival.